JCVI: Influenza A Virus Molecular Virology Techniques.
Section Banner



Zhou B, Wentworth DE

Influenza A Virus Molecular Virology Techniques.

Methods in molecular biology (Clifton, N.J.). 2012 Aug 01; 865: 175-92.

External Citation


Molecular biological techniques for genomic analysis and for creation of recombinant viruses are critical tools in our efforts to understand and combat influenza A viruses. These molecular virology approaches are used in diagnostics, basic research, molecular epidemiology, bioinformatics, and vaccine development. The majority of the techniques used to study this segmented negative-sense RNA virus begin by purifying RNA from the virus, or infected cells, and converting it to cDNA, then to dsDNA, and amplifying that dsDNA using reverse transcription in combination with the polymerase chain reaction (RTPCR). The RTPCR amplicons can be probed, sequenced, or cloned into a variety of vectors for further analysis and to create recombinant influenza A viruses by plasmid-based reverse genetics. To accelerate the amplification and cloning process, we developed multi-segment-RTPCR (M-RTPCR) techniques that efficiently amplify the eight genomic viral RNA segments (vRNAs) of influenza A virus in a single reaction, irrespective of the virus strain. The M-RTPCR amplicons are ideal for nucleotide sequence analysis and cloning full-length vRNAs into plasmids or other vectors designed for protein expression or reverse genetics. Therefore, we also developed modified reverse-genetics plasmids that are designed to rapidly clone M-RTPCR products, or other full-length vRNA amplicons, using recombination-based techniques. The combination of M-RTPCR and recombination-based cloning confers sensitivity, speed, fidelity, and flexibility to the analysis and rescue of any strain/subtype of influenza A virus, without the need for in vitro propagation. The specific topics described in this chapter include purification of high-quality viral RNA, genomic amplification using two different M-RTPCR schemes, sequencing vRNA amplicons, and cloning vRNA amplicons into our modified reverse-genetics plasmids, or commercially available plasmids.